{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:35:48Z","timestamp":1773916548678,"version":"3.50.1"},"reference-count":57,"publisher":"Baishideng Publishing Group Inc.","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2008]]},"DOI":"10.3748\/wjg.14.3681","type":"journal-article","created":{"date-parts":[[2008,7,4]],"date-time":"2008-07-04T04:22:28Z","timestamp":1215145348000},"page":"3681","source":"Crossref","is-referenced-by-count":24,"title":["Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors"],"prefix":"10.3748","volume":"14","author":[{"given":"Martin","family":"Haefner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thilo","family":"Bluethner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Niederhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Moebius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Wittekind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Mossner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Caca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Wiedmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.","DOI":"10.3322\/canjclin.55.1.10"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Lockhart AC, Rothenberg ML, Berlin JD. Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology 2005;128:1642-1654.","DOI":"10.1053\/j.gastro.2005.03.039"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G, Haglund C. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005;54:385-387.","DOI":"10.1136\/gut.2004.047191"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Cardenes HR, Chiorean EG, Dewitt J, Schmidt M, Loehrer P. Locally advanced pancreatic cancer: current therapeutic approach. Oncologist 2006;11:612-623.","DOI":"10.1634\/theoncologist.11-6-612"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.","DOI":"10.1200\/JCO.1997.15.6.2403"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003;21:3402-3408.","DOI":"10.1200\/JCO.2003.09.140"},{"key":"ref7","unstructured":"Cunningham D, Chau I, Stocken D, Davies C, Dunn J, Valle J, Smith D, Steward W, Harper P, Neoptolemos J. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. EJC Supplements 2005;3:4."},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966.","DOI":"10.1200\/JCO.2006.07.9525"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Philip PA, Benedetti J, Fenoglio-Preiser C, Zalupski M, Lenz H, O&rsquo;Reilly E, Wong R, Atkins J, Abruzzese J, Blanke C. Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study. Journal of Clinical Oncology 2007;ASCO Annual Meeting Proceedings Part I 2007; 25:LBA4509.","DOI":"10.1200\/jco.2007.25.18_suppl.lba4509"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23:8033-8040.","DOI":"10.1200\/JCO.2005.01.9661"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz H, McLeod HL, Mulcahy MF, Schilsky RL, Goldberg RM. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB). Journal of Clinical Oncology 2007;ASCO Annual Meeting Proceedings Part I 2007; 25:4508.","DOI":"10.1200\/jco.2007.25.18_suppl.4508"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Hess-Stumpp H. Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur J Cell Biol 2005;84:109-121.","DOI":"10.1016\/j.ejcb.2004.12.010"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Budillon A, Bruzzese F, Di Gennaro E, Caraglia M. Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase. Curr Drug Targets 2005;6:337-351.","DOI":"10.2174\/1389450053765905"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Remiszewski SW, Sambucetti LC, Bair KW, Bontempo J, Cesarz D, Chandramouli N, Chen R, Cheung M, Cornell-Kennon S, Dean K. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with <italic>in vivo<\/italic> antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824). J Med Chem 2003;46:4609-4624.","DOI":"10.1021\/jm030235w"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005;105:1768-1776.","DOI":"10.1182\/blood-2004-09-3413"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M, Yeleswarapu L, Chandramouli N, Perez L, Versace R. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res 2004;64:689-695.","DOI":"10.1158\/0008-5472.CAN-03-2043"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Edwards A, Li J, Atadja P, Bhalla K, Haura EB. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther 2007;6:2515-2524.","DOI":"10.1158\/1535-7163.MCT-06-0761"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006;12:4628-4635.","DOI":"10.1158\/1078-0432.CCR-06-0511"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Rowinsky EK, Pacey S, Patnaik A, O&rsquo;Donnell A, Mita MM, Atadja P, Peng B, Dugan M, Scott JW, De Bono JS. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors. J Clin Oncol 2004;22:abstract 3022 (ASCO 2004).","DOI":"10.1200\/jco.2004.22.90140.3022"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Ottmann OG, Deangelo DJ, Stone DJ, Pfeifer H, Lowenberg B, Atadja P, Peng B, Scott JW, Dugan M, Sonneveld P. A Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies. J Clin Oncol 2004;22:3024.","DOI":"10.1200\/jco.2004.22.14_suppl.3024"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Sharma S, Vogelzang NJ, Beck J, Patnaik A, Mita M, Dugan M, Hwang A, Masson E, Culver KW, Prince H. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589, a novel deacetylase (DAC) inhibitor given intravenously on a new once weekly schedule. J Clin Oncol 2007;25:14019.","DOI":"10.1200\/jco.2007.25.18_suppl.14019"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Prince HM, George D, Patnaik A, Mita M, Dugan M, Butterfoss D, Masson E, Culver KW, Burris HA, Beck J. Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin&rsquo;s lymphoma. J Clin Oncol 2007;25:3500.","DOI":"10.1200\/jco.2007.25.18_suppl.3500"},{"key":"ref23","unstructured":"Ryu B, Jones J, Blades NJ, Parmigiani G, Hollingsworth MA, Hruban RH, Kern SE. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res 2002;62:819-826."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Bruns CJ, Harbison MT, Kuniyasu H, Eue I, Fidler IJ. <italic>In vivo<\/italic> selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia 1999;1:50-62.","DOI":"10.1038\/sj.neo.7900005"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Schoumacher RA, Ram J, Iannuzzi MC, Bradbury NA, Wallace RW, Hon CT, Kelly DR, Schmid SM, Gelder FB, Rado TA. A cystic fibrosis pancreatic adenocarcinoma cell line. Proc Natl Acad Sci USA 1990;87:4012-4016.","DOI":"10.1073\/pnas.87.10.4012"},{"key":"ref26","unstructured":"Meck RA, Clubb KJ, Allen LM, Yunis AA. Inhibition of cell cycle progression of human pancreatic carcinoma cells <italic>in vitro<\/italic> by L-(alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, Acivicin (NSC 163501). Cancer Res 1981;41:4547-4553."},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an <italic>in vitro<\/italic> research platform. Virchows Arch 2003;442:444-452.","DOI":"10.1007\/s00428-003-0784-4"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Tannapfel A, Geissler F, Kockerling F, Katalinic A, Hauss J, Wittekind C. Apoptosis and proliferation in relation to histopathological variables and prognosis in hepatocellular carcinoma. J Pathol 1999;187:439-445.","DOI":"10.1002\/(SICI)1096-9896(199903)187:4<439::AID-PATH272>3.0.CO;2-B"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Tannapfel A, Hahn HA, Katalinic A, Fietkau RJ, Kuhn R, Wittekind CW. Prognostic value of ploidy and proliferation markers in renal cell carcinoma. Cancer 1996;77:164-171.","DOI":"10.1002\/(SICI)1097-0142(19960101)77:1<164::AID-CNCR27>3.0.CO;2-2"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Natoni F, Diolordi L, Santoni C, Gilardini Montani MS. Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways. Biochim Biophys Acta 2005;1745:318-329.","DOI":"10.1016\/j.bbamcr.2005.07.003"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Garcia-Morales P, Gomez-Martinez A, Carrato A, Martinez-Lacaci I, Barbera VM, Soto JL, Carrasco-Garcia E, Menendez-Gutierrez MP, Castro-Galache MD, Ferragut JA. Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. Mol Cancer Ther 2005;4:1222-1230.","DOI":"10.1158\/1535-7163.MCT-04-0186"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Sato N, Ohta T, Kitagawa H, Kayahara M, Ninomiya I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Miwa K. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol 2004;24:679-685.","DOI":"10.3892\/ijo.24.3.679"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Gahr S, Ocker M, Ganslmayer M, Zopf S, Okamoto K, Hartl A, Leitner S, Hahn EG, Herold C. The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells. Int J Oncol 2007;31:567-576.","DOI":"10.3892\/ijo.31.3.567"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Moore PS, Barbi S, Donadelli M, Costanzo C, Bassi C, Palmieri M, Scarpa A. Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim Biophys Acta 2004;1693:167-176.","DOI":"10.1016\/j.bbamcr.2004.07.001"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Cecconi D, Scarpa A, Donadelli M, Palmieri M, Hamdan M, Astner H, Righetti PG. Proteomic profiling of pancreatic ductal carcinoma cell lines treated with trichostatin-A. Electrophoresis 2003;24:1871-1878.","DOI":"10.1002\/elps.200305430"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Arnold NB, Arkus N, Gunn J, Korc M. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 2007;13:18-26.","DOI":"10.1158\/1078-0432.CCR-06-0914"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, Lin YS, Wu CW. Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 2000;275:20436-20443.","DOI":"10.1074\/jbc.M000202200"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY, Bates S, Fojo T. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res 2005;65:7386-7392.","DOI":"10.1158\/0008-5472.CAN-04-3433"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Donadelli M, Costanzo C, Faggioli L, Scupoli MT, Moore PS, Bassi C, Scarpa A, Palmieri M. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog 2003;38:59-69.","DOI":"10.1002\/mc.10145"},{"key":"ref40","unstructured":"Tran H, TShoaf SL. Improved efficacy with sequential use of histone deacetylase inhibitor, LAQ824, with common chemotherapeutic agents in head and neck squamous carcinoma cell lines. Proc Amer Assoc Cancer Res 2005;46:5095."},{"key":"ref41","unstructured":"Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P, Bhalla K. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2003;2:971-984."},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Bluethner T, Niederhagen M, Caca K, Serr F, Witzigmann H, Moebius C, Mossner J, Wiedmann M. Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach. World J Gastroenterol 2007;13:4761-4770.","DOI":"10.3748\/wjg.v13.i35.4761"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood 2003;102:2615-2622.","DOI":"10.1182\/blood-2003-01-0233"},{"key":"ref44","unstructured":"Bhalla KN, Nimmanapalli R, Fuino L, Tao J, Lee H. Histone deacetylase inhibitor LAQ824 down regulates BCR-ABL levels and induces apoptosis of imatinib mesylate -sensitive or -refractory BCR-ABL positive human leukemia cells. Proc Am Soc Clin Oncol 2003;22:2322."},{"key":"ref45","unstructured":"Rosato RR, Almenara JA, Maggio SC, Atadja P, Dent P, Grant S. Potentiation of LAQ824-mediated lethality by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells proceeds through an XIAP- and reactive oxygen species (ROS)-dependent mechanism. Proc Amer Assoc Cancer Res 2005;46:5327."},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N, Atadja P, Pandiella A, San Miguel JF. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006;66:5781-5789.","DOI":"10.1158\/0008-5472.CAN-05-4186"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, Tassone P, Atadja P, Chauhan D, Munshi NC. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006;108:3441-3449.","DOI":"10.1182\/blood-2006-04-016055"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S, Rocha K, Wu J, Giles F, Manley PW. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 2006;108:645-652.","DOI":"10.1182\/blood-2005-11-4639"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res 2006;12:634-642.","DOI":"10.1158\/1078-0432.CCR-05-1132"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Piacentini P, Donadelli M, Costanzo C, Moore PS, Palmieri M, Scarpa A. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch 2006;448:797-804.","DOI":"10.1007\/s00428-006-0173-x"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Richards DA, Boehm KA, Waterhouse DM, Wagener DJ, Krishnamurthi SS, Rosemurgy A, Grove W, Macdonald K, Gulyas S, Clark M. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann Oncol 2006;17:1096-1102.","DOI":"10.1093\/annonc\/mdl081"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Xu S, Furukawa T, Kanai N, Sunamura M, Horii A. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J Hum Genet 2005;50:159-167.","DOI":"10.1007\/s10038-005-0235-y"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Yamada N, Hamada T, Goto M, Tsutsumida H, Higashi M, Nomoto M, Yonezawa S. MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer. Int J Cancer 2006;119:1850-1857.","DOI":"10.1002\/ijc.22047"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Neureiter D, Zopf S, Leu T, Dietze O, Hauser-Kronberger C, Hahn EG, Herold C, Ocker M. Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models. Scand J Gastroenterol 2007;42:103-116.","DOI":"10.1080\/00365520600874198"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Bai J, Demirjian A, Sui J, Marasco W, Callery MP. Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochem Biophys Res Commun 2006;348:1245-1253.","DOI":"10.1016\/j.bbrc.2006.07.185"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Bruns CJ, Koehl GE, Guba M, Yezhelyev M, Steinbauer M, Seeliger H, Schwend A, Hoehn A, Jauch KW, Geissler EK. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res 2004;10:2109-2119.","DOI":"10.1158\/1078-0432.CCR-03-0502"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Bruell D, Bruns CJ, Yezhelyev M, Huhn M, Muller J, Ischenko I, Fischer R, Finnern R, Jauch KW, Barth S. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice. Int J Mol Med 2005;15:305-313.","DOI":"10.3892\/ijmm.15.2.305"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v14\/i23\/3681.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T20:54:28Z","timestamp":1588798468000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v14\/i23\/3681.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":57,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.14.3681","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2008]]}}}